Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure

Journal of Hypertension

Volumn 31, Issue 11, 2013, Pages 2300-2308

  Honda, Nobuhiro ^a   Hirooka, Yoshitaka ^b   Ito, Koji ^a   Matsukawa, Ryuichi ^a   Shinohara, Keisuke ^a   Kishi, Takuya ^b   Yasukawa, Keiji ^c,d   Utsumi, Hideo ^d   Sunagawa, Kenji ^a  

^a Department of Cardiovascular Medicine ^*  (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Department of Molecular Cancer Biology   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

heart failure; hypertension; imidazoline 1 receptor agonist; moxonidine; prognosis; sympathetic nervous system

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; MOXONIDINE; NORADRENALIN; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CANNULATION; CENTRAL SYMPATHOINHIBITION; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE REMODELING; HYPERTENSION; IN VIVO STUDY; MALE; NERVOUS SYSTEM PARAMETERS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RAT; SURVIVAL; SURVIVAL RATE; SYMPATHETIC TONE; TREATMENT OUTCOME; URINARY EXCRETION; WESTERN BLOTTING; ANIMAL; COMPLICATION; DAHL RAT; DRUG EFFECTS; HYPERTROPHY, LEFT VENTRICULAR; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MORTALITY; PATHOPHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; INFUSIONS, INTRAVENTRICULAR; MALE; PROGNOSIS; RATS; RATS, INBRED DAHL; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84885573847     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328364a2a1     Document Type: Article

References (42)

1. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43:2207-2215.
2. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996-1002.
3. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23:1052-1060.
4. Francis GS. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. J Cardiovasc Pharmacol 1998; 32:S16-S21.
5. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al., Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
6. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147:324-330.
7. Fisher JP, Fadel PJ. Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension. Exp Physiol 2010; 95:572-580.
8. Edwards LP, Brown-Bryan TA, McLean L, Ernsberger P. Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther 2012; 30:199-208.
9. Szabo B. Imidazoline antihypertensive drugs: A critical review on their mechanism of action. Pharmacol Ther 2002; 93:1-35.
10. Nikolic K, Agbaba D. Imidazoline antihypertensive drugs: selective I1-imidazoline receptors activation. Cardiovasc Ther 2012; 30:209-216.
11. Chan CK, Burke SL, Zhu H, Piletz JE, Head GA. Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine. Neuroscience 2005; 132:991-1007.
12. Coats AJ. Heart Failure 99-the MOXCON story. Int J Cardiol 1999; 71:109-111.
13. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5:659-667.
14. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33:1058-1066.
15. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, et al. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18:111-120.
16. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103:148-154.
17. Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension 2006; 47:901-911.
18. Dostal DE, Watson LE. Understanding diastolic heart failure with preserved ejection fraction: Choosing the right model. Hypertension 2006; 47:830-832.
19. Peng J, Wang YK, Wang LG, Yuan WJ, Su DF, Ni X, et al. Sympathoinhibitory mechanism of moxonidine: role of the inducible nitric oxide synthase in the rostral ventrolateral medulla. Cardiovasc Res 2009; 84:283-291.
20. Peng J, Wu ZT, Wang YK, Yuan WJ, Sun T, Ni X, et al. GABAergic mechanism in the rostral ventrolateral medulla contributes to the hypotension of moxonidine. Cardiovasc Res 2011; 89:473-481.
21. Aceros H, Farah G, Cobos-Puc L, Stabile AM, Noiseux N, Mukkadam-Daher S. Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38MAPK and Akt. Br J Pharmacol 2011; 164:946-957.
22. Mukaddam-Daher S. An "I" on cardiac hypertrophic remodelling: imidazoline receptors and heart disease. Can J Cardiol 2012; 28:590-598.
23. Ito K, Hirooka Y, Matsukawa R, Nakano M, Sunagawa K. Decreased brain sigma-1 receptor contributes to the relationship between heart failure and depression. Cardiovasc Res 2012; 93:33-40.
24. Briest W, Hölzl A, Rassler B, Deten A, Baba HA, Zimmer HG. Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts. Cardiovasc Res 2003; 57:379-387.
25. Matsubara LS, Matsubara BB, Okoshi MP, Cicogna AC, Janicki JS. Alterations in myocardial collagen content affect rat papillary muscle function. Am J Physiol 2000; 279:H1534-H1539.
26. Araki S, Hirooka Y, Kishi T, Yasukawa K, Utsumi H, Sunagawa K. Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. Hypertens Res 2009; 32:1091-1096.
27. Shinohara K, Hirooka Y, Ogawa K, Kishi T, Yasukawa K, Utsumi H, et al. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats. Clin Exp Hypertens 2012; 34:456-462.
28. Anzai K, Saito K, Takeshita K, Takahashi S, Miyazaki H, Shoji H, et al. Assessment of ESR-CT imaging by comparison with autoradiography for the distribution of a blood-brain-barrier permeable spin probe, MCPROXYL, to rodent brain. Magn Reson Imaging 2003; 21:765-772.
29. Swartz HM, Sentjurc M, Morse PD 2nd. Cellular metabolism of watersoluble nitroxides: effect on rate of reduction of cell/nitroxide ratio, oxygen concentrations and permeability of nitroxides. Biochim Biophys Acta 1986; 888:82-90.
30. Takeshita K, Saito K, Ueda J, Anzai K, Ozawa T. Kinetic study on ESR signal decay of nitroxyl radicals, potent redox probes for in vivo ESR spectroscopy, caused by reactive oxygen species. Biochim Biophys Acta 2002; 1573:156-164.
31. Van Kerckhoven R, van Veen TA, Boomsma F, Saxena PR, Schoemaker RG. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol 2000; 397:113-120.
32. Osadchii OE, Norton GR, McKechnie R, Deftereos D, Woodiwiss AJ. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic b-adrenoreceptor activation. Am J Physiol Heart Circ Physiol 2007; 292:H1898-H1905.
33. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res 1989; 64:827-852.
34. Schraeger JA, Canby CA, Rongish BJ, Kawai M, Tomanek RJ. Normal left ventricular diastolic compliance after regression of hypertrophy. J Cardiovasc Pharmacol 1994; 23:349-357.
35. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55:76-82.
36. Mark SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000; 101:365-376.
37. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Nakayama H, et al. Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca2+ regulatory proteins and extracellular matrix. J Hypertens 2003; 21:1737-1745.
38. Wachter R, Schmidt-Schweda S, Westermann D, Post H, Edelmann F, Kasner M, et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J 2009; 30:3027-3036.
39. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T, et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Failure 2008; 10:446-453.
40. Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG. Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Moll Cell Cardiol 2000; 32:273-284.
41. Hirooka Y. Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension. Hypertens Res 2011; 34:407-412.
42. Peterson JR, Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep 2006; 8:232-241.